# Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients

> **NCT07114627** · — · RECRUITING · sponsor: **Erasmus Medical Center** · enrollment: 66 (estimated)

## Conditions studied

- Solid Cancer
- Gastric (Cardia, Body) Cancer
- Esophageal Cancer
- Colorectal Cancer (CRC)

## Interventions

- **DRUG:** Blood sampling for pharmacokinetics

## Key facts

- **NCT ID:** NCT07114627
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-18
- **Primary completion:** 2026-12
- **Final completion:** 2027-06
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07114627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07114627, "Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT07114627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*